2024

Masri, A. et al. (2024) Efficacy and safety of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4. Journal of Cardiac Failure, 30(11), pp. 1439-1448. (doi: 10.1016/j.cardfail.2024.02.020) (PMID:38493832)

Coats, C. J. et al. (2024) Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. European Heart Journal, (doi: 10.1093/eurheartj/ehae590) (PMID:39217447) (Early Online Publication)

Coats, C. J. et al. (2024) Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from from SEQUOIA‐HCM. Journal of the American Heart Association, 13(5), e035993. (doi: 10.1161/JAHA.124.035993) (PMID:39056349)

Heywood, W. E. et al. (2024) A proof of principle 2D spatial proteome mapping analysis reveals distinct regional differences in the cardiac proteome. Life, 14(8), 970. (doi: 10.3390/life14080970) (PMID:39202712) (PMCID:PMC11355120)

Goldie, F. C. and Coats, C. J. (2024) New perspectives on early stage hypertrophic cardiomyopathy: measuring what matters. Circulation: Heart Failure, 17(8), e012093. (doi: 10.1161/CIRCHEARTFAILURE.124.012093) (PMID:39087345)

Maron, M. S. et al. (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. New England Journal of Medicine, 390(20), pp. 1849-1861. (doi: 10.1056/nejmoa2401424) (PMID:38739079)

Goldie, F. C. , Lee, M. M. Y. , Coats, C. J. and Nordin, S. (2024) Advances in multi-modality imaging in hypertrophic cardiomyopathy. Journal of Clinical Medicine, 13(3), 842. (doi: 10.3390/jcm13030842) (PMID:38337535) (PMCID:PMC10856479)

Veeratterapillay, K., Coats, C. J. , Martin, R., Chaudhry, B. and Coats, L. (2024) A case report of complex congenital heart disease co-existing with hypertrophic cardiomyopathy. European Heart Journal: Case Reports, 8(2), ytae038. (doi: 10.1093/ehjcr/ytae038) (PMID:38313326) (PMCID:PMC10836887)

Coats, C. J. et al. (2024) Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design. JACC: Heart Failure, 12(1), pp. 199-215. (doi: 10.1016/j.jchf.2023.10.004) (PMID:38032573)

2023

Glen, C., Adam, S., Coats, C. J. and Lang, N. N. (2023) Reply: Cardiotoxicity of BRAF/MEK inhibitors according to HFA/ICOS cardiotoxicity risk category. JACC: CardioOncology, 5(6), p. 850. (doi: 10.1016/j.jaccao.2023.10.003) (PMID:38204997) (PMCID:PMC10774785)

Owens, A. et al. (2023) Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving Disopyramide: REDWOOD-HCM Cohort 3. Journal of Cardiac Failure, 29(11), pp. 1576-1582. (doi: 10.1016/j.cardfail.2023.07.003) (PMID:37473912)

Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)

Moody, W. E. et al. (2023) British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis. Echo Research and Practice, 10, 13. (doi: 10.1186/s44156-023-00028-7) (PMID:37653443) (PMCID:PMC10468878)

Bourke, J. et al. (2023) Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations. Open Heart, 9(2), e001977. (doi: 10.1136/openhrt-2022-001977) (PMID:36252992) (PMCID:PMC9577913)

Topriceanu, C.-C. et al. (2023) The atrial and ventricular myocardial proteome of end-stage lamin heart disease. Acta Myologica, 42(2-3), pp. 43-52. (doi: 10.36185/2532-1900-339) (PMID:38090549) (PMCID:PMC10712656)

Maron, M. S. et al. (2023) Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 81(1), pp. 34-45. (doi: 10.1016/j.jacc.2022.10.020) (PMID:36599608)

2022

Gillmore, J. D., Reilly, M. M., Coats, C. J. , Cooper, R., Cox, H., Coyne, M. R.E., Green, A. J., McGowan, R., Moody, W. E. and Hawkins, P. N. (2022) Clinical and genetic evaluation of people with or at risk of hereditary ATTR amyloidosis: an expert opinion and consensus on best Practice in Ireland and the UK. Advances in Therapy, 39(6), pp. 2292-2301. (doi: 10.1007/s12325-022-02139-9) (PMID:35419651) (PMCID:PMC9122857)

Coats, C. J. (2022) History of the British Cardiovascular Society. Heart, 108(10), pp. 761-766. (doi: 10.1136/heartjnl-2021-320139) (PMID:35459725)

2020

Patterson, J., Coats, C. and McGowan, R. (2020) Familial dilated cardiomyopathy associated with pathogenic TBX5 variants: Expanding the cardiac phenotype associated with Holt–Oram syndrome. American Journal of Medical Genetics,Part A, 182(7), pp. 1725-1734. (doi: 10.1002/ajmg.a.61635) (PMID:32449309)

Captur, G. et al. (2020) Identification of a multiplex biomarker panel for hypertrophic cardiomyopathy using quantitative proteomics and machine learning. Molecular and Cellular Proteomics, 19(1), pp. 114-127. (doi: 10.1074/mcp.RA119.001586) (PMID:31243064) (PMCID:PMC6944230)

2019

Coats, C.J. , Frenneaux, M.P. and Elliott, P.M. (2019) Hypertrophic cardiomyopathy - need for gene-specific treatment? - Reply. JAMA Cardiology, 4(8), p. 832. (doi: 10.1001/jamacardio.2019.1766) (PMID:31188395)

Coats, C. J. et al. (2019) Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiology, 4(3), pp. 230-235. (doi: 10.1001/jamacardio.2018.4847) (PMID:30725091) (PMCID:PMC6439550)

2018

Coats, C. J. et al. (2018) Proteomic analysis of the myocardium in hypertrophic obstructive cardiomyopathy. Circulation: Genomic and Precision Medicine, 11(12), e001974. (doi: 10.1161/circgen.117.001974) (PMID:30562113)

Coats, C. (2018) The vital role of exercise testing in hypertrophic cardiomyopathy. International Journal of Cardiology, 271, pp. 200-201. (doi: 10.1016/j.ijcard.2018.06.028) (PMID:29921517)

Pries, A. R., Naoum, A., Habazettl, H., Dunkel, M., Preissner, R., Coats, C. J. , Tornada, A., Orso, F., Van de Werf, F. and Wood, D. A. (2018) CardioScape mapping the cardiovascular funding landscape in Europe. European Heart Journal, 39(25), pp. 2423-2430. (doi: 10.1093/eurheartj/ehx106) (PMID:28449050)

Coats, C.J. , Reid, J., Wright, S., Sonecki, P. and Al-Attar, N. (2018) Papillary fibroelastoma arising from left ventricular outflow tract. European Heart Journal: Cardiovascular Imaging, 19(7), p. 826. (doi: 10.1093/ehjci/jey044) (PMID:29608686)

Jackson, A. M., Dalzell, J. R., Walker, N. L., Coats, C. J. , Jhund, P. S. and Petrie, M. C. (2018) Peripartum cardiomyopathy: diagnosis and management. Heart, 104(9), pp. 779-786. (doi: 10.1136/heartjnl-2016-310599) (PMID:29122930)

2017

Vischer, A.S., Connolly, D.,J., Coats, C.J. , Fuentes, V.L., McKenna, W.J., Castelletti, S. and Pantazis, A.A. (2017) Arrhythmogenic right ventricular cardiomyopathy in Boxer dogs: the diagnosis as a link to the human disease. Acta Myologica, 36(3), pp. 135-150. (PMID:29774304) (PMCID:PMC5953225)

2016

Coats, C.J. , Heywood, W.E., McKenna, W.J., Frenneaux, M.P., Mills, K. and Elliott, P.M. (2016) Correction: Novel insights into the pathophysiology of hypertrophic cardiomyopathy using label free quantitative proteomics (Heart (2014) 100, Suppl 3 (A89-A90) DOI: 10.1136/heartjnl- 2014-306118.153). Heart, 100(23), 1898. (doi: 10.1136/heartjnl-2014-306118.153corr1)

2015

Coats, C. J. , Rantell, K., Bartnik, A., Patel, A., Mist, B., McKenna, W. J. and Elliott, P. M. (2015) Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy. Circulation: Heart Failure, 8(6), (doi: 10.1161/CIRCHEARTFAILURE.114.002248) (PMID:26374874)

2013

Aung, N. et al. (2013) Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure. International Journal of Cardiology, 168(3), pp. 1997-2002. (doi: 10.1016/j.ijcard.2012.12.091) (PMID:23351789)

Coats, C.J. and Elliott, P.M. (2013) Genetic biomarkers in hypertrophic cardiomyopathy. Biomarkers in Medicine, 7(4), pp. 505-516. (doi: 10.2217/bmm.13.79) (PMID:23905887)

Coats, C.J. , Gallagher, M.J., Foley, M., O'Mahony, C., Critoph, C., Gimeno, J., Dawnay, A., McKenna, W.J. and Elliott, P.M. (2013) Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. European Heart Journal, 34(32), pp. 2529-2537. (doi: 10.1093/eurheartj/eht070) (PMID:23455360)

Coats, C.J. et al. (2013) Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with Anderson-Fabry disease. American Journal of Cardiology, 111(1), pp. 111-117. (doi: 10.1016/j.amjcard.2012.08.055) (PMID:23040658)

Núñez, L., Gimeno-Blanes, J.R., Rodriguez-Garcia, M.I., Monserrat, L., Zorio, E., Coats, C.J. , McGregor, C.G., Hernandez del Rincon, J.P., Castro-Beiras, A. and Hermida-Prieto, M. (2013) Somatic MYH7, MYBPC3, TPM1, TNNT2 and TNNI3 mutations in sporadic hypertrophic cardiomyopathy. Circulation Journal, 77(9), pp. 2358-2365. (doi: 10.1253/circj.CJ-13-0294) (PMID:23782526)

2012

Coats, C. and Elliott, P. (2012) The collapsing pulse. British Journal of Hospital Medicine, 73(SUPPL.), C78-80. (doi: 10.12968/hmed.2012.73.Sup5.C78) (PMID:22585293)

2011

Calcagnino, M. et al. (2011) Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease. Journal of the American College of Cardiology, 58(1), pp. 88-89. (doi: 10.1016/j.jacc.2011.03.020) (PMID:21700093)

Sado, D.M., Flett, A.S., Cook, C.M., Coats, C.J. , Quarta, G., Hasleton, J.M., Hausenloy, D.J., Elliott, P.M. and Moon, J.C. (2011) The quantification and role of diffuse myocardial fibrosis in familial dilated cardiomyopathy - an equilibrium contrast cmr study. Journal of Cardiovascular Magnetic Resonance, 13(S1), O108. (doi: 10.1186/1532-429X-13-S1-O108) (PMCID:PMC3106613)

Articles

Masri, A. et al. (2024) Efficacy and safety of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4. Journal of Cardiac Failure, 30(11), pp. 1439-1448. (doi: 10.1016/j.cardfail.2024.02.020) (PMID:38493832)

Coats, C. J. et al. (2024) Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. European Heart Journal, (doi: 10.1093/eurheartj/ehae590) (PMID:39217447) (Early Online Publication)

Coats, C. J. et al. (2024) Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from from SEQUOIA‐HCM. Journal of the American Heart Association, 13(5), e035993. (doi: 10.1161/JAHA.124.035993) (PMID:39056349)

Heywood, W. E. et al. (2024) A proof of principle 2D spatial proteome mapping analysis reveals distinct regional differences in the cardiac proteome. Life, 14(8), 970. (doi: 10.3390/life14080970) (PMID:39202712) (PMCID:PMC11355120)

Goldie, F. C. and Coats, C. J. (2024) New perspectives on early stage hypertrophic cardiomyopathy: measuring what matters. Circulation: Heart Failure, 17(8), e012093. (doi: 10.1161/CIRCHEARTFAILURE.124.012093) (PMID:39087345)

Maron, M. S. et al. (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. New England Journal of Medicine, 390(20), pp. 1849-1861. (doi: 10.1056/nejmoa2401424) (PMID:38739079)

Goldie, F. C. , Lee, M. M. Y. , Coats, C. J. and Nordin, S. (2024) Advances in multi-modality imaging in hypertrophic cardiomyopathy. Journal of Clinical Medicine, 13(3), 842. (doi: 10.3390/jcm13030842) (PMID:38337535) (PMCID:PMC10856479)

Veeratterapillay, K., Coats, C. J. , Martin, R., Chaudhry, B. and Coats, L. (2024) A case report of complex congenital heart disease co-existing with hypertrophic cardiomyopathy. European Heart Journal: Case Reports, 8(2), ytae038. (doi: 10.1093/ehjcr/ytae038) (PMID:38313326) (PMCID:PMC10836887)

Coats, C. J. et al. (2024) Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design. JACC: Heart Failure, 12(1), pp. 199-215. (doi: 10.1016/j.jchf.2023.10.004) (PMID:38032573)

Glen, C., Adam, S., Coats, C. J. and Lang, N. N. (2023) Reply: Cardiotoxicity of BRAF/MEK inhibitors according to HFA/ICOS cardiotoxicity risk category. JACC: CardioOncology, 5(6), p. 850. (doi: 10.1016/j.jaccao.2023.10.003) (PMID:38204997) (PMCID:PMC10774785)

Owens, A. et al. (2023) Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving Disopyramide: REDWOOD-HCM Cohort 3. Journal of Cardiac Failure, 29(11), pp. 1576-1582. (doi: 10.1016/j.cardfail.2023.07.003) (PMID:37473912)

Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)

Moody, W. E. et al. (2023) British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis. Echo Research and Practice, 10, 13. (doi: 10.1186/s44156-023-00028-7) (PMID:37653443) (PMCID:PMC10468878)

Bourke, J. et al. (2023) Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations. Open Heart, 9(2), e001977. (doi: 10.1136/openhrt-2022-001977) (PMID:36252992) (PMCID:PMC9577913)

Topriceanu, C.-C. et al. (2023) The atrial and ventricular myocardial proteome of end-stage lamin heart disease. Acta Myologica, 42(2-3), pp. 43-52. (doi: 10.36185/2532-1900-339) (PMID:38090549) (PMCID:PMC10712656)

Maron, M. S. et al. (2023) Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 81(1), pp. 34-45. (doi: 10.1016/j.jacc.2022.10.020) (PMID:36599608)

Gillmore, J. D., Reilly, M. M., Coats, C. J. , Cooper, R., Cox, H., Coyne, M. R.E., Green, A. J., McGowan, R., Moody, W. E. and Hawkins, P. N. (2022) Clinical and genetic evaluation of people with or at risk of hereditary ATTR amyloidosis: an expert opinion and consensus on best Practice in Ireland and the UK. Advances in Therapy, 39(6), pp. 2292-2301. (doi: 10.1007/s12325-022-02139-9) (PMID:35419651) (PMCID:PMC9122857)

Coats, C. J. (2022) History of the British Cardiovascular Society. Heart, 108(10), pp. 761-766. (doi: 10.1136/heartjnl-2021-320139) (PMID:35459725)

Patterson, J., Coats, C. and McGowan, R. (2020) Familial dilated cardiomyopathy associated with pathogenic TBX5 variants: Expanding the cardiac phenotype associated with Holt–Oram syndrome. American Journal of Medical Genetics,Part A, 182(7), pp. 1725-1734. (doi: 10.1002/ajmg.a.61635) (PMID:32449309)

Captur, G. et al. (2020) Identification of a multiplex biomarker panel for hypertrophic cardiomyopathy using quantitative proteomics and machine learning. Molecular and Cellular Proteomics, 19(1), pp. 114-127. (doi: 10.1074/mcp.RA119.001586) (PMID:31243064) (PMCID:PMC6944230)

Coats, C.J. , Frenneaux, M.P. and Elliott, P.M. (2019) Hypertrophic cardiomyopathy - need for gene-specific treatment? - Reply. JAMA Cardiology, 4(8), p. 832. (doi: 10.1001/jamacardio.2019.1766) (PMID:31188395)

Coats, C. J. et al. (2019) Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiology, 4(3), pp. 230-235. (doi: 10.1001/jamacardio.2018.4847) (PMID:30725091) (PMCID:PMC6439550)

Coats, C. J. et al. (2018) Proteomic analysis of the myocardium in hypertrophic obstructive cardiomyopathy. Circulation: Genomic and Precision Medicine, 11(12), e001974. (doi: 10.1161/circgen.117.001974) (PMID:30562113)

Coats, C. (2018) The vital role of exercise testing in hypertrophic cardiomyopathy. International Journal of Cardiology, 271, pp. 200-201. (doi: 10.1016/j.ijcard.2018.06.028) (PMID:29921517)

Pries, A. R., Naoum, A., Habazettl, H., Dunkel, M., Preissner, R., Coats, C. J. , Tornada, A., Orso, F., Van de Werf, F. and Wood, D. A. (2018) CardioScape mapping the cardiovascular funding landscape in Europe. European Heart Journal, 39(25), pp. 2423-2430. (doi: 10.1093/eurheartj/ehx106) (PMID:28449050)

Coats, C.J. , Reid, J., Wright, S., Sonecki, P. and Al-Attar, N. (2018) Papillary fibroelastoma arising from left ventricular outflow tract. European Heart Journal: Cardiovascular Imaging, 19(7), p. 826. (doi: 10.1093/ehjci/jey044) (PMID:29608686)

Jackson, A. M., Dalzell, J. R., Walker, N. L., Coats, C. J. , Jhund, P. S. and Petrie, M. C. (2018) Peripartum cardiomyopathy: diagnosis and management. Heart, 104(9), pp. 779-786. (doi: 10.1136/heartjnl-2016-310599) (PMID:29122930)

Vischer, A.S., Connolly, D.,J., Coats, C.J. , Fuentes, V.L., McKenna, W.J., Castelletti, S. and Pantazis, A.A. (2017) Arrhythmogenic right ventricular cardiomyopathy in Boxer dogs: the diagnosis as a link to the human disease. Acta Myologica, 36(3), pp. 135-150. (PMID:29774304) (PMCID:PMC5953225)

Coats, C.J. , Heywood, W.E., McKenna, W.J., Frenneaux, M.P., Mills, K. and Elliott, P.M. (2016) Correction: Novel insights into the pathophysiology of hypertrophic cardiomyopathy using label free quantitative proteomics (Heart (2014) 100, Suppl 3 (A89-A90) DOI: 10.1136/heartjnl- 2014-306118.153). Heart, 100(23), 1898. (doi: 10.1136/heartjnl-2014-306118.153corr1)

Coats, C. J. , Rantell, K., Bartnik, A., Patel, A., Mist, B., McKenna, W. J. and Elliott, P. M. (2015) Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy. Circulation: Heart Failure, 8(6), (doi: 10.1161/CIRCHEARTFAILURE.114.002248) (PMID:26374874)

Aung, N. et al. (2013) Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure. International Journal of Cardiology, 168(3), pp. 1997-2002. (doi: 10.1016/j.ijcard.2012.12.091) (PMID:23351789)

Coats, C.J. and Elliott, P.M. (2013) Genetic biomarkers in hypertrophic cardiomyopathy. Biomarkers in Medicine, 7(4), pp. 505-516. (doi: 10.2217/bmm.13.79) (PMID:23905887)

Coats, C.J. , Gallagher, M.J., Foley, M., O'Mahony, C., Critoph, C., Gimeno, J., Dawnay, A., McKenna, W.J. and Elliott, P.M. (2013) Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. European Heart Journal, 34(32), pp. 2529-2537. (doi: 10.1093/eurheartj/eht070) (PMID:23455360)

Coats, C.J. et al. (2013) Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with Anderson-Fabry disease. American Journal of Cardiology, 111(1), pp. 111-117. (doi: 10.1016/j.amjcard.2012.08.055) (PMID:23040658)

Núñez, L., Gimeno-Blanes, J.R., Rodriguez-Garcia, M.I., Monserrat, L., Zorio, E., Coats, C.J. , McGregor, C.G., Hernandez del Rincon, J.P., Castro-Beiras, A. and Hermida-Prieto, M. (2013) Somatic MYH7, MYBPC3, TPM1, TNNT2 and TNNI3 mutations in sporadic hypertrophic cardiomyopathy. Circulation Journal, 77(9), pp. 2358-2365. (doi: 10.1253/circj.CJ-13-0294) (PMID:23782526)

Coats, C. and Elliott, P. (2012) The collapsing pulse. British Journal of Hospital Medicine, 73(SUPPL.), C78-80. (doi: 10.12968/hmed.2012.73.Sup5.C78) (PMID:22585293)

Calcagnino, M. et al. (2011) Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease. Journal of the American College of Cardiology, 58(1), pp. 88-89. (doi: 10.1016/j.jacc.2011.03.020) (PMID:21700093)

Sado, D.M., Flett, A.S., Cook, C.M., Coats, C.J. , Quarta, G., Hasleton, J.M., Hausenloy, D.J., Elliott, P.M. and Moon, J.C. (2011) The quantification and role of diffuse myocardial fibrosis in familial dilated cardiomyopathy - an equilibrium contrast cmr study. Journal of Cardiovascular Magnetic Resonance, 13(S1), O108. (doi: 10.1186/1532-429X-13-S1-O108) (PMCID:PMC3106613)